Apeloa Pharmaceutical announced it will invest 3.46 million yuan to participate in the establishment of Zhejiang Ante Yutai Biotechnology Company. The company signed an investment agreement with Hengdian Company, Zhenyu Taibo Yutai, and Yuan Yutai on July 15, 2026, to jointly set up the new firm with a registered capital of 10 million yuan. Apeloa Pharmaceutical subscribed for 3.46 million yuan, accounting for 34.58 percent. The company stated that this investment aligns with its strategic layout, aiming to enter the high-growth biopharmaceutical sector, enrich its product pipeline, and optimize its business structure. In the first quarter of 2026, Apeloa Pharmaceutical reported revenue of 2.447 billion yuan and net profit attributable to the parent company of 249 million yuan.
Apeloa Pharmaceutical Co LtdCompany invests 3.46 million yuan in a biotech joint venture to enter high-growth biopharma sector, enriching product pipeline.